NOTE: In 2021, Satellos executed a reverse takeover of iCo Therapeutics Inc., undertook a concurrent capital raise and began trading on the TSX-V under the ticker "MSCL".

------------------------------------------------------------

iCo Therapeutics is a "Search and Development" company. By focusing efforts on development instead of research, iCo's business model aims to acquire the rights to drugs that are either off-patent, currently approved or near commercialization and develop them by redosing or reformulating them for new or expanded labels. Subsequent development of these therapeutics may include drug delivery technologies-such as sustained release or biodegradable matrices to extend patent coverage.

There is a significant decrease in development risk associated with targeting existing drugs, including:

• Reduced risk of adverse events since clinical testing and systemic use in humans has already been established.
• Scale-up and manufacturing issues have already been addressed since clinical grade material has been made.
• The target and mechanism of action has been identified.